Evaluation of the Validity of Preemptive Therapy against Cytomegalovirus Disease Based on Antigenemia Assay with a Cutoff of 20 Positive Cells per Two Slides

BACKGROUND: Preemptive therapy with ganciclovir (GCV) based on the results of a cytomegalovirus (CMV) antigenemia assay is a standard strategy for preventing CMV disease after allogeneic hematopoietic cell transplantation (HCT). However, the appropriate threshold of antigenemia-positive cells for de...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Kana, Nakasone, Hideki, Wada, Hidenori, Yamasaki, Ryoko, Ishihara, Yuko, Kawamura, Koji, Ashizawa, Masahiro, Sato, Miki, Terasako-Saito, Kiriko, Machishima, Tomohito, Kimura, Shun-Ichi, Kikuchi, Misato, Kako, Shinichi, Kanda, Junya, Yamazaki, Rie, Tanihara, Aki, Nishida, Junji, Kanda, Yoshinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764037/
https://www.ncbi.nlm.nih.gov/pubmed/24040054
http://dx.doi.org/10.1371/journal.pone.0073754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764037/
https://www.ncbi.nlm.nih.gov/pubmed/24040054
http://dx.doi.org/10.1371/journal.pone.0073754

Ejemplares similares